Research programme: histone deacetylase inhibitors - TopoTargetAlternative Names: HDAC inhibitors - TopoTarget
Latest Information Update: 28 Mar 2011
At a glance
- Originator TopoTarget
- Class Small molecules
- Mechanism of Action Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer; Huntington's disease; Malaria; Psoriasis
Most Recent Events
- 28 Nov 2003 Preclinical trials in Cancer in Denmark (unspecified route)